Loading…
Loading…
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bank of New York Mellon Corp purchased a new stake in Revvity Inc. (NYSE: RVTY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 707,941 shares of the company's stock, valued at approximately $78,766,000. Bank of New York Mellon Corp
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
On August 19, 2026, Revvity Inc (RVTY) shares rose by 5.0% to a current price of $119.45, moving within a 52-week range of $81.22 to $122.11. This upward moveme
Assenagon Asset Management S.A. lessened its stake in Revvity Inc. (NYSE: RVTY) by 35.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,483 shares of the company's stock after selling 8,540 shares during the quarter. Assenagon Asset Management